Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

Core Viewpoint - Scilex Holding Company is advancing a business combination with Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, focusing on non-opioid pain management products, with the SEC declaring the registration statement effective [1][6]. Company Overview - Scilex is dedicated to acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [5]. - The company’s commercial products include ZTlido, ELYXYB, and Gloperba, targeting high unmet medical needs [5]. Business Combination Details - An extraordinary general meeting for Denali shareholders is scheduled for September 3, 2025, to approve the proposed business combination [2][6]. - The combined company will be renamed Semnur Pharmaceuticals, Inc. upon closing the business combination [6]. Product Pipeline - Scilex has three product candidates: SP-102 (SEMDEXA), SP-103, and SP-104, targeting various pain management needs and conditions [7]. - SP-102 is a novel gel formulation for epidural injections, while SP-103 is a next-generation lidocaine topical system [7]. Market Position - Scilex aims to address significant market opportunities in non-opioid therapies for pain management, focusing on improving patient outcomes [5].